© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes
June 23, 2025
ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.
FDA Approves Clesrovimab for RSV LRTD Prevention in Infants: Daily Dose
June 23, 2025
Your daily dose of the clinical news you may have missed.
5 Late-Breaking Clinical Trials in Obesity to Watch at the ADA 85th Scientific Sessions, June 20-24, 2025
June 20, 2025
Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.
ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions
June 20, 2025
The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults
June 20, 2025
Dupilumab is the first targeted treatment for B to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.
Dual GLP-1/GLP-2 Agonist Dapiglutide Achieves 11.6% Mean Weight Loss at 28 Weeks in Phase 1b Trial
June 20, 2025
The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.
FDA OKs First Biologic to Treat COPD with Eosinophilic Phenotype: Daily Dose
June 20, 2025
Your daily dose of the clinical news you may have missed.
Teledermatology-Dermoscopy Program Could Help Reduce Inequities in Skin Cancer Screening
June 20, 2025
A student-led teledermatology-dermoscopy initiative that identified skin lesions in underserved communities could be a scalable model for early skin cancer detection and care.
Atopic Dermatitis in Focus: 3 Expert Pearls for Primary Care
June 19, 2025
RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.
Johann Gudjonsson, MD, PhD, on Emerging AD Therapies: From Single Targets to Combination Approaches
June 19, 2025
RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.